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OBJECTIVE: To characterize MAAE related to CVC replace-
ment or placement among hospitalized Medicare surgical
patients. METHODS: The Centers for Medicare and Medicaid
Services sponsored identiﬁcation and abstraction of the records
for 40,620 hospitalizations of Medicare beneﬁciaries. Different
simple random sampling fractions were used for each of the 50
states. For patients undergoing surgery in the operating room,
details about each CVC (re-)placed during the hospitalization,
and related non-infectious adverse events, were noted.
RESULTS: Among 40,620 sample hospitalizations, 7044 CVCs
were (re-)placed during 4889 surgical hospitalizations (mean
length of stay 10.4d [95% CI: 9.7–11.2]); among these, there
were 159 MAAEs among 130 hospitalizations (mean length of
stay 20.1d [95% CI: 15.8–24.5]). The proportion of MAAEs per
catheter (re-)placement was 2.3% (95% CI: 1.9%–2.6%) and
the proportion of stays where a CVC was (re-)placed that had a
CVC-related MAAE was 2.7% (95% CI : 2.2%–3.2%). Among
patients who had length of stay up to 12 days and a CVC (re-
)placement, MAAE was associated with increased in-hospital
mortality (OR = 2.88, 95% CI: 1.53–5.43). Among those 
with CVCs (re-)placed, MAAE occurrence was unrelated to age.
The most common CVC (re-)placement sites were internal
jugular (40%) and subclavian veins (25%). The most common
speciﬁed CVC types were PICCs (19%) and pulmonary artery
catheters (16%). The most common hospital locations for (re-
)placement were operating rooms (35%) and critical care units
(17%). Most (72%) of the stays with CVC (re-)placement had
just 1; 20% had 2 CVC (re-)placements. The most common
MAAEs were misplacement (22%), thrombosis or embolism
(18%), coiling or kinking (10%), and pneumothorax (8%).
CONCLUSIONS: Among Medicare surgical inpatients, the 
rate of mechanical or allergic adverse events per catheter was
approximately 2%. Incomplete documentation was a barrier 
to studying speciﬁc types of CVCs in relation to MAAEs and
their risk factors.
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EXPLORATION OF HIGHLY ELEVATED CREATININE KINASE
RESULTS AND ASSOCIATED CHOLESTEROL THERAPY IN A
LARGE COMMERCIAL HEALTH PLAN
Harley C1, Kempf J2, Nelson M1, Riedel A1
1Ingenix, Eden Prairie, MN, USA; 2AstraZeneca LP, Wilmington, DE,
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OBJECTIVE: The use of statins has been associated with risk
for myotoxicity. Myopathy, deﬁned as creatine kinase (CK) ele-
vation greater than 10 times the upper limit of normal (ULN),
occurs in 0.1–0.5% of statin users. This study describes elevated
CK levels in an HMO population on cholesterol lowering
therapy. METHODS: All subjects with a valid CK result during
January 1 to December 31, 2001 were studied. Pharmacy claims
data were linked to the laboratory results. A highly elevated
result was deﬁned as CK at least 10 ULN. RESULTS: A search
of laboratory data identiﬁed 13,624 subjects with valid CK
results. Most subjects had only one result (n = 10,301, 76%).
Seventy-six subjects (0.6%) had a highly elevated CK result.
Forty-one percent of all subjects (n = 5530) ﬁlled prescriptions
for statins only, 400 (3%) ﬁlled prescriptions for non-statin cho-
lesterol lowering therapy only, and 1473 (11%) ﬁlled prescrip-
tions for both types of cholesterol lowering medications. Highly
elevated CK results were found among 0.3% (n = 14) of statin
only subjects, 0.5% (n = 2) of non-statin therapy only subjects
and 0.6% (n = 9) of subjects with both medications. Of subjects
with no cholesterol therapy, 0.8% (n = 53 of 6621) had a highly
elevated CK result. CONCLUSIONS: We found a low rate of
highly elevated CK results among those for whom results were
available. The rate of highly elevated CK was higher among
those with non-statin cholesterol therapy or combination
therapy compared to those with statin therapy alone. Despite the
low occurrence of highly elevated results, we found that a large
percentage of those tested were statin users. The low incidence
of highly elevated CK among monitored statin users raises 
questions regarding the most effective strategy for identifying
patients at risk for myotoxicity.
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THE NATIONAL ANTICOAGULATION BENCHMARK AND
OUTCOMES REPORT (NABORTM): EVIDENCE OF A
SIGNIFICANT DIFFERENCE BETWEEN GUIDELINES AND
ACTUAL PRACTICE 
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OBJECTIVE: To assess patient characteristics, risk factors and
antithrombotic treatment of atrial ﬁbrillation (AF), venous
thromboembolism (VTE), acute myocardial infarction (AMI),
and prophylaxis in orthopedic surgery (OS) in patients enrolled
in a national multicenter anticoagulation database. METHODS:
Data was retrospectively collected from hospital inpatient
records at 38 US hospitals. Patients treated from July 2000—
June 2003 with an ICD-9-CM or procedure code for AF, pul-
monary embolus (PE), DVT, pregnancy related PE or DVT, AMI,
total knee hip or knee replacement, and hip fracture surgery were
randomly selected. Patients under 18 years of age, and those
admitted from or discharged to another hospital were excluded.
Clinical characteristics and anticoagulation management accord-
ing to guidelines were analyzed. RESULTS: A total of 3778
patients were included (945 AF, 939 VTE, 966 AMI, and OS).
Mean age was 66.1 years with 53.3% male and 46.7% female.
Comorbidities included hypertension (59.9%), coronary artery
disease (35.5%), diabetes (21.5%), and malignancy (17.3%).
Surprisingly only 54.7% of AF patients with high stroke-risk
received warfarin and 20.6% received no treatment. Only 50.6%
of VTE patients had INR ≥ 2.0 two consecutive days prior to
discontinuing heparin. Only 60.5% of those without a thera-
peutic INR were discharged on bridge therapy. Length of hospi-
talization for bridged patients was signiﬁcantly less than those
discharged on chronic warfarin alone (4.0 vs. 8.1 days) (P <
0.001). Only 75.5% of AMI patients received aspirin on arrival
to the hospital, although 88% were discharged on aspirin and/or
warfarin. Only 85.6% of the OS population received prophy-
laxis with heparin or LMWH, the remaining received no anti-
coagulation. CONCLUSIONS: These results suggest that
evidence-based antithrombotic guidelines are not being consis-
tently followed. Further evaluation of antithrombotic practices
in those sites with the highest and lowest performance is 
warranted. It is hoped that this database will help demonstrate
gaps between guidelines and actual practice.
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OBESITY AMONG HIGH SCHOOL STUDENT AND
CONTRIBUTING FACTORS
Williams BD, Xiao H
Florida Agricultural & Mechanical University,Tallahassee, FL, USA
OBJECTIVE: The basis of this study is to explore the different
contributing factors that affect excess weight gain among ado-
lescents. The different attributes that will be reviewed include:
the various genetic disorders, nutrition, food industry, physical
activity, sedentary activities, and the assortment of methods used
to measure to weight and body composition. METHODS: The
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design of this study is a cross sectional study using secondary
data. The sampling frame will include high school students. The
method of sample selection used is the clustering sampling
method. The unit of analysis is at the individual level. The study
population is high school students. The dependent variable is
weight and independent variables are: height, diet, nutrition,
exercising, age, sex, race and self-perception. RESULTS: The
model was very representational of the study population r2 =
0.584. The statistical signiﬁcance level was 0.05 and many vari-
ables (Height, Gender, Ethnicity, Age, etc.) proved to have a
strong signiﬁcant affect on weight (Beta was also used). CON-
CLUSIONS: The limitation of the study is that the survey fails
to ask any question regarding genetic disorders that inﬂuence
excessive weight gain, obesity. This information would be
formable in trying to treat adolescents who currently suffer from
genetic disorders. Also this would provide a good estimate of the
percentage of young people (by ethnicity) who are affected.
Another survey is recommended; that ask an assortment of ques-
tions pertaining to the daily habits of adolescents, a social behav-
ioral study. The information could aid in the development of a
better behavioral treatment for children in accordance to their
life style. The Youth Risk Behavioral Survey needs to be modi-
ﬁed so that it is more inclusive. The survey should be translated
into other languages and made available for students who are
not ﬂuent in comprehending English. Non-English speaking 
children do gain weight as well.
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DOES THE RATE OF MEDICARE MANAGED-CARE
PENETRATION AFFECT AVAILABILITY OF RESOURCES FOR
HEART FAILURE TREATMENT?
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OBJECTIVES: The HF-ACTION trial evaluates the effectiveness
of exercise as an intervention for heart failure patients. To assess
generalizability of study ﬁndings, we included a survey of par-
ticipating site characteristics as part of the study. We hypothe-
sized that rates of Medicare managed care penetration would
inﬂuence site heart failure care strategies. METHODS: Survey
items were developed based on a literature review and clinicians’
input. Sites were divided into high- and low-penetration groups
according to their counties’ rates of Medicare managed care pen-
etration. Rates were obtained from the Centers for Medicare and
Medicaid Services, and high- and low-penetration categories
were delineated by the sample median. Simple statistics were
used to describe the sample. Wilcoxon rank-sums and ∏ 2 tests
were used to test for differences between areas of high and low
managed care penetration. RESULTS: We received 47 of 50
surveys, a response rate of 94%. We found considerable varia-
tion in the availability of certain resources between areas of low
and high managed care penetration. Institutions located in high-
penetration areas were more likely than those in low-penetration
areas to treat heart failure outpatients in geriatric clinics (100%
vs. 0%, p = 0.014), to have IV diuretics available in clinic (100%
vs. 80%, p = 0.049) and to use clinics for acute care (40% vs.
11%, p = 0.044). Availability of heart failure service (96% vs.
79%, p = 0.057), availability of nutritionist in clinic (45% 
vs. 74%, p = 0.069) and use of ER for acute care episodes (85%
vs. 61%, p = 0.095) also varied by degree of managed care pen-
etration. Use of BNP blood test did not vary signiﬁcantly in inpa-
tient (high—39% vs. low—58%, p = 0.210) or outpatient
settings (50% vs. 47%, p = 0.860). CONCLUSIONS: Our
assessment in a clinical trial setting suggests that available
resources vary by degree of managed care penetration. This 
variability should be considered when analyzing the HF-
ACTION data as it could affect patient care and outcomes.
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GASTRIC BYPASS SURGERY—AN OVERVIEW
Misra S
Rush University Medical Center, Chicago, IL, USA
OBJECTIVE: Evaluating gastric bypass surgery in obese
patients. METHODS: From March 1999 to December 2002,
106 obese patients underwent gastric bypass operations by a
single surgeon in a tertiary care hospital in the Midwest. The
data is extracted from the clinical charts and evaluated statisti-
cally using SPSS software. The relationship between body mass
index (BMI) of patients, type of operation performed, operating
time, length of stay (LOS) in the hospital, presence of co-mor-
bidities and payer type are analyzed. RESULTS: Fifty-six and 51
patients underwent open and laparoscopic bypass surgeries
respectively. The mean BMI is 53.96 with minimum of 36.1 and
maximum of 85.2 with the mean overall LOS being 4.22 days
with minimum of 2 and maximum 28 days. The mean LOS for
open and laparoscopic gastric bypass surgery is 5 and 3 days
respectively. The mean operating time for the open and laparo-
scopic methods are 165 and 175 minutes respectively. LOS is
positively correlated with BMI (p < 0 .05, r = 0.248), the number
of pre-existing medical conditions (p < 0.05, r = 0.218), open
surgery (p < 0.01, r = 0.323) but negatively correlated with
laparoscopic surgery (p < 0.01, r = -0.306) while intensive care
usage is positively correlated with BMI and open surgery (p <
0.01, r = 0.350 and 0.250) but is negatively correlated with
laparoscopic procedures (p < 0.01, r = -0.266). Pulse rates
greater than 110/minute on second and third post-operative days
is associated with total operating time (p < 0.01, r = 0.370) and
with post-operative leak from anastomosis on ﬁrst and third
post-operative days (p < 0.05 and 0.01, r = 0.228 and 0.272)
respectively. BMI is also positively associated with public 
aid patients but is negatively associated with private payers.
CONCLUSION: Being an increasingly popular surgery for 
obese people, gastric bypass procedures need to be carefully 
evaluated long-term for optimum clinical and economic out-
comes in view of the above ﬁndings.
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RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS
OF BETA-BLOCKER THERAPY IN CONGESTIVE HEART
FAILURE PATIENTS IN A MANAGED CARE ENVIRONMENT
Thaker DJ, Godley PJ, Browne BA, Rohack J, Houck P
Scott & White,Temple,TX, USA
OBJECTIVE: Beta-blocker utilization in patients with mild to
moderate congestive heart failure (CHF) substantially improves
left ventricular ejection fraction and patient symptoms and
reduces overall mortality. Carvedilol and extended-release meto-
prolol succinate are the only beta-blocking agents currently indi-
cated in the US for CHF patients. Both agents have shown similar
risk reduction in overall and cause-speciﬁc mortality; however,
no comparative outcomes data for the two agents are available.
This study identiﬁes current utilization patterns (agent/dosing
regimens) of beta-blocker therapy in the CHF population at Scott
& White Health Plan. METHODS: Health plan pharmacy
claims data were retrospectively reviewed for calendar year 2002
for beta-blocker prescribing patterns for CHF patients (identi-
ﬁed by ICD-9 codes). Speciﬁcally, pharmacy claims were evalu-
ated for inclusion of beta-blockers as standard therapy for CHF,
use of FDA-approved versus off-label use of beta-blockers for
CHF, and use of recommended doses. RESULTS: Approximately
1700 health plan CHF patients were identiﬁed; 40% of those
